Back to Search
Start Over
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
- Source :
-
Circulation journal : official journal of the Japanese Circulation Society [Circ J] 2006 Aug; Vol. 70 (8), pp. 995-1000. - Publication Year :
- 2006
-
Abstract
- Background: Angiotensin II receptor blockers (ARB) are now commonly used to treat hypertension because of their beneficial effects on cardiovascular remodeling. However, ARB treatment can not inhibit the left ventricular (LV) remodeling sufficiently, which may be related with aldosterone secretion. To inhibit the action of aldosterone during ARB treatment, the additional effects of an aldosterone blocker and spironolactone (SPRL) on LV hypertrophy in patients with essential hypertension was studied.<br />Methods and Results: The patients with essential hypertension were randomly divided into 2 groups; 1 group was treated with an ARB, candesartan (8 mg/day), for 1 year (ARB group) and other group was treated with the ARB for the first 6 months and with the ARB plus SPRL (25 mg/day) for the next 6 months (combination group). Seventy patients who underwent echocardiography every 6 months were analyzed and were also classified into 4 subgroups of LV geometric pattern according to the LV mass index (LVMI) and the relative wall thickness (RWT). The ARB treatment and the addition of SPRL significantly reduced the blood pressure, however, both treatments did not affect the LV geometry in both groups. The ARB treatment in the subgroups of concentric LV remodeling (RWT>or=0.45 and LVMI<125) and concentric LV hypertrophy (RWT>or=0.45 and LVMI>or=125) significantly reduced RWT. However, ARB treatment in all subgroups did not affect LVMI. The addition of SPRL only in the concentric LV hypertrophy subgroup significantly reduced the LVMI, despite similar changes in blood pressure.<br />Conclusions: These results indicated that the addition of SPRL treatment during the ARB treatment and conventional treatments is clinically useful to reduce the LVMI in hypertensive patients with concentric LV hypertrophy; however, does not improve the eccentric LV hypertrophy.
- Subjects :
- Aged
Aldosterone blood
Aldosterone physiology
Angiotensin II blood
Angiotensin II Type 1 Receptor Blockers pharmacology
Benzimidazoles pharmacology
Biphenyl Compounds
Blood Pressure drug effects
Blood Pressure physiology
Echocardiography
Female
Heart Ventricles drug effects
Heart Ventricles pathology
Hemodynamics drug effects
Hemodynamics physiology
Humans
Hypertension complications
Hypertension pathology
Hypertrophy, Left Ventricular etiology
Male
Middle Aged
Mineralocorticoid Receptor Antagonists pharmacology
Natriuretic Peptide, Brain blood
Spironolactone pharmacology
Tetrazoles pharmacology
Ventricular Remodeling drug effects
Angiotensin II Type 1 Receptor Blockers therapeutic use
Benzimidazoles therapeutic use
Hypertension drug therapy
Hypertrophy, Left Ventricular pathology
Mineralocorticoid Receptor Antagonists therapeutic use
Spironolactone therapeutic use
Tetrazoles therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1346-9843
- Volume :
- 70
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Circulation journal : official journal of the Japanese Circulation Society
- Publication Type :
- Academic Journal
- Accession number :
- 16864931
- Full Text :
- https://doi.org/10.1253/circj.70.995